TY - JOUR
T1 - Mini-beam as salvage chemotherapy for refractory hodgkin's disease and non-hodgkin's lymphoma
AU - Stewart, A. Keith
AU - Brandwein, Joseph M.
AU - Sutcliffe, Simon B.
AU - Scott, J. Gerald
AU - Keating, Armand
N1 - Funding Information:
Acknowledgements The authors wish to express their gratitude to Dr. A. Goldstone and professor D. C. Linch for generously providing the MiniBEAM protocol for use in Toronto. This work was supported by the National Cancer Institute of Canada. Dr. Keating is a Senior Research Scientist of the Institute.
PY - 1991
Y1 - 1991
N2 - Long-term disease-free survival after conventional dose salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) is rare. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) is regarded by many as the treatment of choice. For lymphoma, eligibility for transplant is frequently restricted to cases with chemotherapy-sensitive disease or minimal tumour bulk. We evaluated the mini-BEAM regimen as further treatment for patients unresponsive to initial salvage therapy and thus ineligible for ABMT at our centre. Carmustine 60 mg/m2 I.V. day one, etoposide 75 mg/m2 I.V. days 2-5, cytosine arabinoside 100 mg/m2 I.V. q12h days 2-5 and melphalan 30 mg/m2 day 6 (mini-BEAM) was administered to 24 patients with lymphoma, 22 of whom were refractory to at least first-line salvage chemotherapy. Eleven had HD and 13 NHL. The complete response (CR) rate was 21% and the overall response was 59%. Febrile neutropenia occurred in 48% of treatment episodes. There were two treatment-related deaths. Thirteen patients underwent bone marrow transplantation (BMT), 11 received ABMT (8 HD, 3 NHL). Six patients did not achieve remission after transplant but 7 patients remain in continuous CR, with a follow-up of 6-17 months post-transplant. Consequently, 7 of 24 (29%) patients responded to mini-BEAM and many achieve long-term disease-free survival after BMT. Further evaluation of mini-BEAM as a salvage regimen prior to BMT is indicated.
AB - Long-term disease-free survival after conventional dose salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) is rare. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) is regarded by many as the treatment of choice. For lymphoma, eligibility for transplant is frequently restricted to cases with chemotherapy-sensitive disease or minimal tumour bulk. We evaluated the mini-BEAM regimen as further treatment for patients unresponsive to initial salvage therapy and thus ineligible for ABMT at our centre. Carmustine 60 mg/m2 I.V. day one, etoposide 75 mg/m2 I.V. days 2-5, cytosine arabinoside 100 mg/m2 I.V. q12h days 2-5 and melphalan 30 mg/m2 day 6 (mini-BEAM) was administered to 24 patients with lymphoma, 22 of whom were refractory to at least first-line salvage chemotherapy. Eleven had HD and 13 NHL. The complete response (CR) rate was 21% and the overall response was 59%. Febrile neutropenia occurred in 48% of treatment episodes. There were two treatment-related deaths. Thirteen patients underwent bone marrow transplantation (BMT), 11 received ABMT (8 HD, 3 NHL). Six patients did not achieve remission after transplant but 7 patients remain in continuous CR, with a follow-up of 6-17 months post-transplant. Consequently, 7 of 24 (29%) patients responded to mini-BEAM and many achieve long-term disease-free survival after BMT. Further evaluation of mini-BEAM as a salvage regimen prior to BMT is indicated.
KW - MiniBEAM
KW - Refractory Hodgkin's disease
KW - Refractory non-Hodgkin's lymphoma
KW - Salvage chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0025915995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025915995&partnerID=8YFLogxK
U2 - 10.3109/10428199109068113
DO - 10.3109/10428199109068113
M3 - Article
AN - SCOPUS:0025915995
SN - 1042-8194
VL - 5
SP - 111
EP - 115
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2-3
ER -